Furthermore, the remarkable sensitivity of the anti-CCP2 antibody test, which enables detection years before clinical symptoms manifest, offers great potential as a predictive marker for early intervention and enhanced RA disease management, thereby minimizing the risk of cardiovascular disease, including stroke. The gene discussed is AGBL2; the disease is Stroke.